Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients

NCT03228836 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Effect of Drugs

Interventions

DRUG: Sintilimab

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.